Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype

Journal of Clinical Investigation

Volumn 116, Issue 6, 2006, Pages 1582-1595

  Kaposi Novak, Pal ^a   Lee, Ju Seog ^a   Gòmez Quiroz, Luis ^a   Coulouarn, Cédric ^a   Factor, Valentina M ^a   Thorgeirsson, Snorri S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SCATTER FACTOR RECEPTOR;

ADULT; ANGIOGENESIS; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL MOTILITY; CLUSTER ANALYSIS; CONTROLLED STUDY; CYTOSKELETON; FEMALE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GENOME ANALYSIS; HUMAN; HUMAN CELL; LIVER CELL; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELLS, CULTURED; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HEPATOCYTES; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, GROWTH FACTOR; SURVIVAL RATE;

EID: 33745220780     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI27236     Document Type: Article

References (58)

1. Rhodes, D.R., and Chinnaiyan, A.M. 2005. Integrative analysis of the cancer transcriptome. Nat. Genet. 37(Suppl.):S31-S37.
2. Rhodes, D.R., et al. 2004. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia. 6:1-6.
3. Rhodes, D.R., et al. 2004. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc. Natl. Acad. Sci. U. S. A. 101:9309-9314.
4. Segal, E., Friedman, N., Kaminski, N., Regev, A., and Koller, D. 2005. From signatures to models: understanding cancer using microarrays. Nat. Genet. 37(Suppl.):S38-S45.
5. Sweet-Cordero, A., et al. 2005. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. Nat. Genet. 37:48-55.
6. Huang, E., et al. 2003. Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat. Genet. 34:226-230.
7. Furge, K.A., Zhang, Y.W., and Vande Woude, G.F. 2000. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 19:5582-5589.
8. Gentile, A., and Comoglio, P.M. 2004. Invasive growth: a genetic program. Int. J. Dev. Biol. 48:451-456.
9. Schmidt, C., et al. 1995. Scatter factor/hepatocyte growth factor is essential for liver development. Nature. 373:699-702.
10. Bladt, F., Riethmacher, D., Isenmann, S., Aguzzi, A., and Birchmeier, C. 1995. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature. 376:768-771.
11. Michalopoulos, G.K., and DeFrances, M.C. 1997. Liver regeneration. Science. 276:60-66.
12. Ueki, T., et al. 1999. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat. Med. 5:226-230.
13. Schulze-Bergkamen, H., et al. 2004. Hepatocyte growth factor induces Mcl-1 in primary human hepatocytes and inhibits CD95-mediated apoptosis via Akt. Hepatology. 39:645-654.
14. Wang, X., et al. 2002. A mechanism of cell survival: sequestration of Fas by the HGF receptor Met. Mol. Cell. 9:411-421.
15. Stolz, D.B., Mars, W.M., Petersen, B.E., Kim, T.H., and Michalopoulos, G.K. 1999. Growth factor signal transduction immediately after two-thirds partial hepatectomy in the rat. Cancer Res. 59:3954-3960.
16. Birchmeier, C., Birchmeier, W., Gherardi, E., and Vande Woude, G.F. 2003. Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. 4:915-925.
17. Ma, P.C., Maulik, G., Christensen, J., and Salgia, R. 2003. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22:309-325.
18. Corso, S., Comoglio, P.M., and Giordano, S. 2005. Cancer therapy: can the challenge be MET? Trends Mol. Med. 11:284-292.
19. Ueki, T., Fujimoto, J., Suzuki, T., Yamamoto, H., and Okamoto, E. 1997. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma. Hepatology. 25:862-866.
20. Huh, C.G., et al. 2004. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. U. S. A. 101:4477-4482.
21. Medico, E., et al. 2001. Osteopontin is an autocrine mediator of hepatocyte growth factor-induced invasive growth. Cancer Res. 61:5861-5868.
22. Gujdar, A., Sipeki, S., Bander, E., Buday, L., and Farago, A. 2004. Protein kinase C modulates negatively the hepatocyte growth factor-induced migration, integrin expression and phosphatidylinositol 3-kinase activation. Cell. Signal. 16:505-513.
23. Recio, J.A., and Merlino, G. 2003. Hepatocyte growth factor/scatter factor induces feedback upregulation of CD44v6 in melanoma cells through Egr-1. Cancer Res. 63:1576-1582.
24. Lipschutz, J.H., Li, S., Arisco, A., and Balkovetz, D.F. 2005. Extracellular signal-regulated kinases 1/2 control claudin-2 expression in Madin-Darby canine kidney strain I and II cells. J. Biol. Chem. 280:3780-3788.
25. Baron, V., Adamson, E.D., Calogero, A., Ragona, G., and Mercola, D. 2006. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 13:115-124.
26. Kempiak, S.J., et al. 2005. A neural Wiskott-Aldrich Syndrome protein-mediated pathway for localized activation of actin polymerization that is regulated by cortactin. J. Biol. Chem. 280:5836-5842.
27. Moriyama, K., and Yahara, I. 2002. Human CAP1 is a key factor in the recycling of cofilin and actin for rapid actin turnover. J. Cell Sci. 115:1591-1601.
28. McClatchey, A.I. 2003. Merlin and ERM proteins: unappreciated roles in cancer development? Nat. Rev. Cancer. 3:877-883.
29. Guo, W., and Giancotti, F.G. 2004. Integrin signalling during tumour progression. Nat. Rev. Mol. Cell Biol. 5:816-826.
30. Wai, P.Y., and Kuo, P.C. 2004. The role of Osteopontin in tumor metastasis. J. Surg. Res. 121:228-241.
31. Dickinson, D.A., et al. 2004. Human glutamate cysteine ligase gene regulation through the electrophile response element. Free Radic. Biol. Med. 37:1152-1159.
32. Motohashi, H., and Yamamoto, M. 2004. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 10:549-557.
33. Dhakshinamoorthy, S., and Jaiswal, A.K. 2000. Small maf (MafG and MafK) proteins negatively regulate antioxidant response element-mediated expression and antioxidant induction of the NAD(P)H:Quinone oxidoreductase1 gene. J. Biol. Chem. 275:40134-40141.
34. Stahl, S., et al. 2005. Genotype-phenotype relationships in hepatocellular tumors from mice and man. Hepatology. 42:353-361.
35. Lee, J.S., et al. 2004. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology. 40:667-676.
36. Lee, J.-S., et al. 2006. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat. Med. 12:410-416.
37. Chen, X., et al. 2002. Gene expression patterns in human liver cancers. Mol. Biol. Cell. 13:1929-1939.
38. Lee, J.S., et al. 2004. Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat. Genet. 36:1306-1311.
39. Strohmeyer, D., et al. 2004. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res. 24:1797-1804.
40. Kuhnen, C., et al. 2003. Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density. J. Cancer Res. Clin. Oncol. 129:415-422.
41. Denko, N., et al. 2000. Epigenetic regulation of gene expression in cervical cancer cells by the tumor microenvironment. Clin. Cancer Res. 6:480-487.
42. Kinch, M.S., and Carles-Kinch, K. 2003. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer. Clin. Exp. Metastasis. 20:59-68.
43. MacDonald, T.J., et al. 2001. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat. Genet. 29:143-152.
44. Bardelli, A., et al. 1999. Concomitant activation of pathways downstream of Grb2 and PI 3-kinase is required for MET-mediated metastasis. Oncogene. 18:1139-1146.
45. Pollard, T.D., and Borisy, G.G. 2003. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 112:453-465.
46. Sherman, M. 2005. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin. Liver Dis. 25:143-154.
47. Okabe, H., et al. 2001. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res. 61:2129-2137.
48. Iizuka, N., et al. 2003. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet. 361:923-929.
49. Ye, Q.H., et al. 2003. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 9:416-423.
50. Giordano, S., et al. 2002. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat. Cell Biol. 4:720-724.
51. Fischer, O.M., Giordano, S., Comoglio, P.M., and Ullrich, A. 2004. Reactive oxygen species mediate Met receptor transactivation by G protein-coupled receptors and the epidermal growth factor receptor in human carcinoma cells. J. Biol. Chem. 279:28970-28978.
52. Jo, M., et al. 2000. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J. Biol. Chem. 275:8806-8811.
53. Gerritsen, M.E., Tomlinson, J.E., Zlot, C., Ziman, M., and Hwang, S. 2003. Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells. Br. J. Pharmacol. 140:595-610.
54. Lee, J.M., Calkins, M.J., Chan, K., Kan, Y.W., and Johnson, J.A. 2003. Identification of the NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in primary cortical astrocytes using oligonucleotide microarray analysis. J. Biol. Chem. 278:12029-12038.
55. Matsushima-Nishiwaki, R., et al. 2003. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis. 24:1353-1359.
56. Park, E.Y., Cho, I.J., and Kim, S.G. 2004. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res. 64:3701-3713.
57. Kao, C.Y., Factor, V.M., and Thorgeirsson, S.S. 1996. Reduced growth capacity of hepatocytes from c-myc and c-myc/TGF-α transgenic mice in primary culture. Biochem. Biophys. Res. Commun. 222:64-70.
58. Pfaffl, M.W., Horgan, G.W., and Dempfle, L. 2002. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 30:e36.